A Very Rare Case of Cutaneous Toxicity of API Protocol

Filali N1*, Touimi SH2, Akimana G1, Elkacemi H1, El Mouhtadi S1, Abahssain H1, Kebdani T3, Benjaafar N2 and Errihani H1

1Department of Oncology, National Institute of Oncology, Rabat, Morocco
2Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco

1. Abstract

It's a 36 years old female patient treated 7 years ago for an osteochondroma of the upper third of the left humerus by surgery alone. She was under follow-up since then. Five months ago, she presented a mass in the same previous location. CT scan showed a locally advanced tumor of the left humerus.

2. Clinical Image

It's a 36 years old female patient treated 7 years ago for an osteochondroma of the upper third of the left humerus by surgery alone. She was under follow-up since then. Five months ago, she presented a mass in the same previous location. CT scan showed a locally advanced tumor of the left humerus.

A biopsy of the mass showed a low-grade osteosarcoma with high-grade osteosarcoma differentiation foci.

The remainder of the staging didn't reveal any metastases.

The patient received 1 course of chemotherapy neoadjuvant to surgery with Adriamycin – Cisplatin – Ifosfamide (API). She presented 3 days later right laterocervical skin lesions which extend in one week to the homolateral upper hemithorax, likely related to rare cutaneous toxicity of the protocol.

Figure: A 36 years old patient with a rare cutaneous toxicity of API protocol